Dopamine News and Research

Latest Dopamine News and Research

Research shows how dopamine contributes to sex differences in worms

Dopamine is responsible for sex-specific variations in common behaviors, finds a study of worm movements published in JNeurosci.

From Society for Neuroscience 16 Apr 2019

New quantum material effectively detects early signs of neurological diseases

What if the brain could detect its own disease? Researchers have been trying to create a material that "thinks" like the brain does, which would be more sensitive to early signs of neurological diseases such as Parkinson's.

11 Apr 2019

Innovative drug delivery may alleviate Parkinson's symptoms and stop its progression

Parkinson's disease affects between 7 and 10 million people worldwide and the number of people diagnosed is soaring due to the ageing population.

10 Apr 2019

Alcohol, Cannabis and Other Drugs: A Pharmacological Evaluation

Understanding the interactions between alcohol and cannabis can provide researchers, clinicians and other HCPs with important information on the severity of their side effects.

10 Apr 2019

New study debunks link between depression risk and 18 genes

Over the past quarter-century, researchers have published hundreds of studies suggesting a small set of particular genes or gene-variants plays a substantial role in boosting susceptibility to depression.

3 Apr 2019

Neuroscientists develop new model to trial preventative treatments for schizophrenia

Neuroscientists at The University of Queensland have developed a new animal model of schizophrenia that will enable researchers around the world to better understand the disease and develop new treatments.

30 Mar 2019

Researchers develop new technology to mass produce cerebral cortex neurons

Korea Brain Research Institute (KBRI, President Pann Ghill Suh) announced on Mar. 4 that its research team led by principal researcher Yoichi Kosodo developed a technology to mass produce cerebral cortex neurons utilizing Induced pluripotent Stem Cells.

28 Mar 2019

NIH starts clinical trial of drug to treat cravings associated with opioid use disorder

A clinical trial of an experimental drug designed to treat cravings associated with opioid use disorder has begun in the National Institutes of Health Clinical Center.

22 Mar 2019

ADHD drug raising risk of psychosis

A new study has found that teenagers and youngsters who are treated with amphetamines such as Adderall are at a greater risk of developing psychosis compared to patients who are on other drugs such as Ritalin. The results of the study were published in the latest issue of the New England Journal of Medicine.

21 Mar 2019

New drugs on PBS for Parkinson's, MND and Cutaneous T cell lymphoma

Under Australia's Pharmaceutical Benefits Scheme (PBS), soon many of the rare diseases and their treatments are set to become cheaper.

21 Mar 2019

Roundworm study suggests alternatives for treatment of schizophrenia

A group of Brazilian scientists have long conducted experiments with roundworms to investigate the role of schizophrenia-linked genes in patients' response to antipsychotic drugs. The results obtained thus far point to new ways of understanding resistance to certain classes of medication.

20 Mar 2019

Researchers measure brain metabolite levels in people with mild memory problems

Using strong and targeted but noninvasive magnets at specific sites in the brains of people with and without mild learning and memory problems, Johns Hopkins researchers report they were able to detect differences in the concentrations of brain chemicals that transmit messages between neurons.

20 Mar 2019

Scientists identify brain circuit responsible for cocaine-seeking behavior during relapse

Approximately 1.5 million Americans use cocaine in a given year, according to the National Institute on Drug Abuse. Many are repeat users. Unfortunately, there are currently no FDA-approved medicinal treatments for cocaine addiction.

19 Mar 2019

Study unravels how cancer medication works in brains of Parkinson's patients

Laboratory analysis from the first arm of a phase II clinical trial testing the use of nilotinib in patients with Parkinson's disease demonstrates precisely how the agent increases levels of dopamine in the brains of study participants, says a research team at Georgetown University Medical Center. Symptoms of Parkinson's, such as motor dysfunction, are a result of a dopamine loss.

13 Mar 2019